StockNews.com Begins Coverage on Cara Therapeutics (NASDAQ:CARA)

Research analysts at StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note issued to investors on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Trading Down 6.1 %

Shares of NASDAQ:CARA opened at $0.36 on Tuesday. The stock has a market capitalization of $19.47 million, a PE ratio of -0.20 and a beta of 0.64. Cara Therapeutics has a 1 year low of $0.23 and a 1 year high of $1.15. The firm has a fifty day moving average price of $0.31 and a 200 day moving average price of $0.31.

Institutional Trading of Cara Therapeutics

A number of hedge funds have recently bought and sold shares of CARA. Disciplined Growth Investors Inc. MN lifted its position in shares of Cara Therapeutics by 6.6% in the 2nd quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares during the period. XTX Topco Ltd bought a new position in shares of Cara Therapeutics during the 3rd quarter worth about $29,000. Finally, FMR LLC boosted its position in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 32,789 shares in the last quarter. 44.66% of the stock is owned by institutional investors.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.